Kalaris Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

Reuters

Nov 08, 2025

Kalaris <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <klrs.oq> expected to post a loss of 65 cents a share - Earnings Preview </klrs.oq>

Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to report resultson November 10 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 65 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $20.00, about 76.3% above its last closing price of $4.75

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jun. 30 2025	-0.53	-0.52	-0.61	Missed	-17.3
Mar. 31 2025	-0.75	-0.77	-2.52	Missed	-225.2

Jun. 30 2024	-1.61	-2.41	-1.15	Beat	52.4
Mar. 31 2024	-3.81	-3.60	-5.98	Missed	-66
Dec. 31 2023	-10.66	-9.84	-8.28	Beat	15.9
Sep. 30 2023	-9.40	-9.57	-8.97	Beat	6.3

This summary was machine generated November 7 at 22:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581783277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581783277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581783277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581783277","market":"nz","top_or_hot":-1,"title":"Kalaris Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <klrs.oq> expected to post a loss of 65 cents a share - Earnings Preview </klrs.oq></title></head><body><ul><li><p>Kalaris Therapeutics Inc <span>KLRS.OQ</span> <span>KLRS.O</span> is expected to  report resultson November 10 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 65 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $20.00, about 76.3% above its last closing price of $4.75</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.53</p></td><td><p>-0.52</p></td><td><p>-0.61</p></td><td><p>Missed</p></td><td><p>-17.3</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.75</p></td><td><p>-0.77</p></td><td><p>-2.52</p></td><td><p>Missed</p></td><td><p>-225.2</p></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.61</p></td><td><p>-2.41</p></td><td><p>-1.15</p></td><td><p>Beat</p></td><td><p>52.4</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-3.81</p></td><td><p>-3.60</p></td><td><p>-5.98</p></td><td><p>Missed</p></td><td><p>-66</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-10.66</p></td><td><p>-9.84</p></td><td><p>-8.28</p></td><td><p>Beat</p></td><td><p>15.9</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-9.40</p></td><td><p>-9.57</p></td><td><p>-8.97</p></td><td><p>Beat</p></td><td><p>6.3</p></td></tr></tbody></table><p>This summary was machine generated November 7 at 22:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kalaris Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalaris Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-08 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <klrs.oq> expected to post a loss of 65 cents a share - Earnings Preview </klrs.oq></title></head><body><ul><li><p>Kalaris Therapeutics Inc <span>KLRS.OQ</span> <span>KLRS.O</span> is expected to  report resultson November 10 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 65 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $20.00, about 76.3% above its last closing price of $4.75</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.53</p></td><td><p>-0.52</p></td><td><p>-0.61</p></td><td><p>Missed</p></td><td><p>-17.3</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.75</p></td><td><p>-0.77</p></td><td><p>-2.52</p></td><td><p>Missed</p></td><td><p>-225.2</p></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-1.61</p></td><td><p>-2.41</p></td><td><p>-1.15</p></td><td><p>Beat</p></td><td><p>52.4</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-3.81</p></td><td><p>-3.60</p></td><td><p>-5.98</p></td><td><p>Missed</p></td><td><p>-66</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-10.66</p></td><td><p>-9.84</p></td><td><p>-8.28</p></td><td><p>Beat</p></td><td><p>15.9</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-9.40</p></td><td><p>-9.57</p></td><td><p>-8.97</p></td><td><p>Beat</p></td><td><p>6.3</p></td></tr></tbody></table><p>This summary was machine generated November 7 at 22:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ31X:1","article_id":"2581783277","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581783277","pubTimestamp":1762555806,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kalaris Therapeutics Inc  expected to post a loss of65cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  report resultson November 10 (estimated) for the period e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KLRS":"Kalaris Therapeutics Inc."},"translate_title":"Kalaris Therapeutics Inc预计每股亏损65美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLRS":0.9},"content_text":"Kalaris Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  report resultson November 10 (estimated) for the period ending September 30 2025LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 65 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $20.00, about 76.3% above its last closing price of $4.75Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jun. 30 2025-0.53-0.52-0.61Missed-17.3Mar. 31 2025-0.75-0.77-2.52Missed-225.2Jun. 30 2024-1.61-2.41-1.15Beat52.4Mar. 31 2024-3.81-3.60-5.98Missed-66Dec. 31 2023-10.66-9.84-8.28Beat15.9Sep. 30 2023-9.40-9.57-8.97Beat6.3This summary was machine generated November 7 at 22:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}